Tab. Montilet
Tablet · PO · 10mg / tablet · 1 tablet
৳15.05
Tab.
Montilet
Montelukast Sodium
— Amulet Pharmaceuticals Ltd.
10mg / tablet
Presentations
Dose rules
No structured dose rules are linked to this brand yet.
Dose reference
Human
Adults & adolescents (15 years & older)- Asthma & Allergic Rhinitis: 10 mg/day Exercise-Induced Bronchoconstriction: 10 mg/day Pediatric patients (6 to 14 years)- Asthma & Allergic Rhinitis: 5 mg/day Exercise-Induced Bronchoconstriction: 5 mg/day Pediatric patients (6 months to 5 years)- Asthma & Allergic Rhinitis: 4 mg/day Exercise-Induced Bronchoconstriction: Not recommended Patients with both asthma and allergic rhinitis should take only one dose daily in the evening. For prevention of Acute prevention of Exercise-Induced Bronchoconstriction, a single dose should be taken at least 2 hours before exercise.
Administration: Route of administration: Oral. Montelukast may be taken with or without food or as directed by the physician.
Clinical notes
Applications:
- Rhinitis
Indication Notes:
Montelukast Sodium is indicated for: Prophylaxis and chronic treatment of asthma Acute prevention of Exercise-Induced Bronchoconstriction (EIB) Relief of symptoms of Allergic Rhinitis (AR): Seasonal & Perennial Allergic Rhinitis
Avoid In:
N/A
Contraindication Notes:
Montelukast is contraindicated in patients who are hypersensitive to any component of this product.
Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene receptor (CysLT1). The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma & allergic rhinitis, including airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.
With medicine: No dose adjustment is needed when montelukast is co-administered with theophylline, prednisone, prednisolone, terfenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative-hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, oral contraceptives, and Cytochrome P450 (CYP) enzyme inducers.With food and others: Bioavailability and other conditions were not significantly observed with food & other conditions.
Common: Diarrhoea, fever, gastrointestinal discomfort, headache, nausea, vomiting, skin reactions, upper respiratory tract infection.Uncommon: Akathisia, anxiety, arthralgia, asthenia, abnormal behavior, depression, dizziness, drowsiness, dry mouth, haemorrhage, irritability, malaise, muscle complaints, oedema, seizure, abnormal sensation, sleep disorders.Rare: Angioedema, concentration impaired, disorientation, eosinophilic granulomatosis with polyangiitis, erythema nodosum, hallucination, hepatic disorders, memory loss, palpitations, pulmonary eosinophilia, suicidal tendencies, tremor.
There were no adverse experiences in the majority of overdosage reports. The most frequently occurring adverse experiences were consistent with the safety profile of Montelukast and included abdominal pain, somnolence, thirst, headache, vomiting and psychomotor hyperactivity. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.
There are no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed. Montelukast is excreted in breast milk. So caution should be exercised when Montelukast is given to a nursing mother.
Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmatic. Neuropsychiatric events including agitation, hostility, anxiousness, depression, disorientation, disturbance in attention, dream abnormalities, hallucinations, insomnia, irritability, memory impairment, restlessness, somnambulism, suicidal thinking and behavior (including suicide) and tremor.